Sir, Colistin is now widely used to treat infections caused by MDR Gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. 1 The pharmacokinetics (PK) of colistin, available for parenteral use as colistin methanesulfonate (CMS), which requires metabolization to the active form of colistin, are highly variable especially amongst critically ill patients with varying degrees of renal impairment. 2 Colistin has a concentration-dependent activity and narrow therapeutic window; therefore, therapeutic drug monitoring may represent a useful clinical tool to optimize individual dosage and plasma concentrations, possibly optimizing the antibacterial effect, minimizing the emergence of resistance and reducing colistin-induced side effects. 1 An average steady-state plasma colistin concentration of 2 mg/L has been considered a reasonable target value for infective pathogens with an MIC ,1 mg/L. 1 Few PK data are available in burn patients: a population PK analysis by Lee et al. 3 and three case reports were published. 4 -6 As the clinical interest in optimizing colistin plasma concentrations is increasing, we aimed to describe the PK of colistin treatment in eight patients with Acinetobacter infections admitted to a burn unit.
Patients were treated with CMS twice daily by intravenous infusion after appropriate loading dose adjustment for kidney impairment, which occurred in the majority of patients. 7 Blood samples were collected at 0, 1, 3, 5 and 12 h after administration, at steady-state. Colistin and CMS plasma concentrations were determined by two previously reported chromatographic methods with some modifications. 8, 9 Colistin was extracted using protein precipitation with acetonitrile containing 0.1% trifluoroacetic acid; the supernatant was diluted 1 :1 with water. The CMS concentration was calculated by subtraction of colistin from total colistin after hydrolysis with sulphuric acid (0.5 M). The analysis was performed using an UPLC/MS-MS system. Chromatographic separation was done on an ACQUITY UPLC HSS T3 1.8 mm (2.1×150 mm) column (Waters, Milford, MA, USA), protected by an ACQUITY UPLC Column MIU, million international units; AUC 0 -12 , area under the concentration -time curve from 0 to 12 h; C trough , plasma concentration measured immediately before drug intake (at steady-state); C max , plasma concentration measured after 1 h from the beginning of the infusion; t 1/2 , half-life; CL, clearance; V, volume of distribution; NA, not available.
